142 related articles for article (PubMed ID: 29953583)
41. IGHV3-21 gene usage is associated with high TCL1 expression in chronic lymphocytic leukemia.
Mansouri MR; Sevov M; Aleskog A; Jondal M; Merup M; Sundström C; Osorio L; Rosenquist R
Eur J Haematol; 2010 Feb; 84(2):109-16. PubMed ID: 19889012
[TBL] [Abstract][Full Text] [Related]
42. The prognostic role of CXCR3 expression by chronic lymphocytic leukemia B cells.
Ocaña E; Delgado-Pérez L; Campos-Caro A; Muñóz J; Paz A; Franco R; Brieva JA
Haematologica; 2007 Mar; 92(3):349-56. PubMed ID: 17339184
[TBL] [Abstract][Full Text] [Related]
43. Constitutive activation of NF-κB signaling by NOTCH1 mutations in chronic lymphocytic leukemia.
Xu ZS; Zhang JS; Zhang JY; Wu SQ; Xiong DL; Chen HJ; Chen ZZ; Zhan R
Oncol Rep; 2015 Apr; 33(4):1609-14. PubMed ID: 25633905
[TBL] [Abstract][Full Text] [Related]
44. Differential gene expression profile associated to apoptosis induced by dexamethasone in CLL cells according to IGHV/ZAP-70 status.
Baptista MJ; Muntañola A; Calpe E; Abrisqueta P; Salamero O; Fernández E; Codony C; Giné E; Kalko SG; Crespo M; Bosch F
Clin Cancer Res; 2012 Nov; 18(21):5924-33. PubMed ID: 22966019
[TBL] [Abstract][Full Text] [Related]
45. Global histone deacetylase enzymatic activity is an independent prognostic marker associated with a shorter overall survival in chronic lymphocytic leukemia patients.
Van Damme M; Crompot E; Meuleman N; Mineur P; Dessars B; El Housni H; Bron D; Lagneaux L; Stamatopoulos B
Epigenetics; 2014 Oct; 9(10):1374-81. PubMed ID: 25437053
[TBL] [Abstract][Full Text] [Related]
46. Divergent expression of cyclin-dependent kinase inhibitors (CKI) and p14ARF/p16 beta in non-Hodgkin's lymphomas and chronic lymphocytic leukemia.
Pabst T; Peters UR; Tinguely M; Schwaller J; Tschan M; Aebi S; Vonlanthen S; Borisch B; Betticher DC; Zimmermann A; Tobler A; Fey MF
Leuk Lymphoma; 2000 May; 37(5-6):639-48. PubMed ID: 11042528
[TBL] [Abstract][Full Text] [Related]
47. Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI.
Delgado J; Doubek M; Baumann T; Kotaskova J; Molica S; Mozas P; Rivas-Delgado A; Morabito F; Pospisilova S; Montserrat E
Am J Hematol; 2017 Apr; 92(4):375-380. PubMed ID: 28120419
[TBL] [Abstract][Full Text] [Related]
48. Prognostic relevance of serum levels and cellular expression of adiponectin in B-cell chronic lymphocytic leukemia.
Molica S; Vitelli G; Cutrona G; Todoerti K; Mirabelli R; Digiesi G; Giannarelli D; Sperduti I; Molica M; Gentile M; Morabito F; Neri A; Ferrarini M
Int J Hematol; 2008 Nov; 88(4):374-380. PubMed ID: 18818986
[TBL] [Abstract][Full Text] [Related]
49. UGT2B17 expression: a novel prognostic marker within IGHV-mutated chronic lymphocytic leukemia?
Bhoi S; Baliakas P; Cortese D; Mattsson M; Engvall M; Smedby KE; Juliusson G; Sutton LA; Mansouri L
Haematologica; 2016 Feb; 101(2):e63-5. PubMed ID: 26589911
[No Abstract] [Full Text] [Related]
50. The histone methyltransferase EZH2 as a novel prosurvival factor in clinically aggressive chronic lymphocytic leukemia.
Papakonstantinou N; Ntoufa S; Chartomatsidou E; Kotta K; Agathangelidis A; Giassafaki L; Karamanli T; Bele P; Moysiadis T; Baliakas P; Sutton LA; Stavroyianni N; Anagnostopoulos A; Makris AM; Ghia P; Rosenquist R; Stamatopoulos K
Oncotarget; 2016 Jun; 7(24):35946-35959. PubMed ID: 27191993
[TBL] [Abstract][Full Text] [Related]
51. Most morphologic features in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) do not reliably predict underlying FISH genetics or immunoglobulin heavy chain variable region somatic mutational status.
Garcia CF; Hunt KE; Kang H; Babb A; Gale JM; Vasef MA; Reichard KK
Appl Immunohistochem Mol Morphol; 2010 Mar; 18(2):119-27. PubMed ID: 19826250
[TBL] [Abstract][Full Text] [Related]
52. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data.
International CLL-IPI working group
Lancet Oncol; 2016 Jun; 17(6):779-790. PubMed ID: 27185642
[TBL] [Abstract][Full Text] [Related]
53. Expression of mutated IGHV3-23 genes in chronic lymphocytic leukemia identifies a disease subset with peculiar clinical and biological features.
Bomben R; Dal-Bo M; Benedetti D; Capello D; Forconi F; Marconi D; Bertoni F; Maffei R; Laurenti L; Rossi D; Del Principe MI; Luciano F; Sozzi E; Cattarossi I; Zucchetto A; Rossi FM; Bulian P; Zucca E; Nicoloso MS; Degan M; Marasca R; Efremov DG; Del Poeta G; Gaidano G; Gattei V
Clin Cancer Res; 2010 Jan; 16(2):620-8. PubMed ID: 20068100
[TBL] [Abstract][Full Text] [Related]
54. Why Is the Immunoglobulin Heavy Chain Gene Mutation Status a Prognostic Indicator in Chronic Lymphocytic Leukemia?
Rozovski U; Keating MJ; Estrov Z
Acta Haematol; 2018; 140(1):51-54. PubMed ID: 30114695
[TBL] [Abstract][Full Text] [Related]
55. Expression of ZAP-70 protein correlates with disease stage in chronic lymphocytic leukemia and is associated with, but not generally restricted to, non-mutated Ig VH status.
Kim SZ; Chow KU; Kukoc-Zivojnov N; Boehrer S; Brieger A; Steimle-Grauer SA; Harder L; Hoelzer D; Mitrou PS; Weidmann E
Leuk Lymphoma; 2004 Oct; 45(10):2037-45. PubMed ID: 15370248
[TBL] [Abstract][Full Text] [Related]
56. Gene expression profiling identifies ARSD as a new marker of disease progression and the sphingolipid metabolism as a potential novel metabolism in chronic lymphocytic leukemia.
Trojani A; Di Camillo B; Tedeschi A; Lodola M; Montesano S; Ricci F; Vismara E; Greco A; Veronese S; Orlacchio A; Martino S; Colombo C; Mura M; Nichelatti M; Colosimo A; Scarpati B; Montillo M; Morra E
Cancer Biomark; 2011-2012; 11(1):15-28. PubMed ID: 22820137
[TBL] [Abstract][Full Text] [Related]
57. FCRL2 mRNA expression is inversely associated with clinical progression in chronic lymphocytic leukemia.
Nückel H; Collins CH; Frey UH; Sellmann L; Dürig J; Siffert W; Dührsen U
Eur J Haematol; 2009 Dec; 83(6):541-9. PubMed ID: 19682311
[TBL] [Abstract][Full Text] [Related]
58. CD49d (ITGA4) expression is a predictor of time to first treatment in patients with chronic lymphocytic leukaemia and mutated IGHV status.
Baumann T; Delgado J; Santacruz R; Martínez-Trillos A; Rozman M; Aymerich M; López C; Costa D; Carrió A; Villamor N; Montserrat E
Br J Haematol; 2016 Jan; 172(1):48-55. PubMed ID: 26559905
[TBL] [Abstract][Full Text] [Related]
59. Overexpression of EZH2 associates with a poor prognosis in chronic lymphocytic leukemia.
Rabello Ddo A; Lucena-Araujo AR; Alves-Silva JC; da Eira VB; de Vasconcellos MC; de Oliveira FM; Rego EM; Saldanha-Araujo F; Pittella Silva F
Blood Cells Mol Dis; 2015 Jan; 54(1):97-102. PubMed ID: 25131810
[TBL] [Abstract][Full Text] [Related]
60. Mantle cell lymphoma displays a homogenous methylation profile: a comparative analysis with chronic lymphocytic leukemia.
Halldórsdóttir AM; Kanduri M; Marincevic M; Mansouri L; Isaksson A; Göransson H; Axelsson T; Agarwal P; Jernberg-Wiklund H; Stamatopoulos K; Sander B; Ehrencrona H; Rosenquist R
Am J Hematol; 2012 Apr; 87(4):361-7. PubMed ID: 22374828
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
